On average, patients at private equity purchased facilities had 25.4% more hospital-acquired conditions, according to the study published Dec. 26 in JAMA.
To get their results, researchers examined data from 662,095 hospitalizations at 51 private equity-acquired hospitals compared with more than 4.1 million hospitalizations at 259 matched control hospitals. They found that despite typically having a lower-risk patient population of Medicare beneficiaries, private equity-purchased hospital patients were still more likely to encounter adverse events.
Specifically, there was a nearly 38% increase in patients with central line–associated bloodstream infections at private equity hospitals and a 27% increase in falls. Surgical site infections for patients at these facilities were doubled, according to researchers, which they wrote, overall means a “poorer quality of inpatient care.”
“Such increases in hospital-acquired infections may result from decreased staffing, changes in operator technique, poorer clinician experience, increased patient illness, or other explanations,” the study authors wrote.
While hospital-acquired infections are typically associated with longer hospital stays, researchers found that not to be the case for private equity-purchased facilities. Instead, there was actually a slight decrease in length of stay for patients there.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
